Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
November 08, 2023 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
November 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Priority Review of resmetirom new drug application underway in the U.S.Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
November 02, 2023 16:05 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
September 28, 2023 22:30 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Proposed Public Offering
September 28, 2023 16:01 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
September 26, 2023 07:30 ET
|
Theratechnologies
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la...
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
September 26, 2023 07:30 ET
|
Theratechnologies
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 millionsBLA for F8 formulation of tesamorelin submitted to FDAAgreement in principle on key amendments to loan facility with...
Theratechnologies annoncera ses résultats du troisième trimestre de l’exercice financier de 2023
September 18, 2023 16:15 ET
|
Theratechnologies
MONTRÉAL, 18 sept. 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement...
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
September 18, 2023 16:15 ET
|
Theratechnologies
MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
September 13, 2023 09:10 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...